AcouSort reaches milestone for AcouPlasma Optical

Report this content

The development process of AcouPlasma Optical has now reached an important milestone. The project has reached “Design freeze”, meaning that the final product design is finished.

AcouPlasma Optical is AcouSort’s first OEM product, aiming to be used as a third-party component that integrates sample preparation into analytical and diagnostic systems. After over a year of product development, the product design has been finalized and the project has reached an important milestone. The next steps are design verification, proving that the product meets its requirements, and manufacturing process validation. The final product will be launched during the fall 2021, but beta evaluation kits are already available to customers.

– This is a significant milestone for AcouSort. Our long-term business strategy is to provide sample preparation modules to the life science industry, and this is an important step towards realizing that strategy. We have been working with the AcouPlasma Optical product development project since early 2020 and are very pleased with the successful execution so far. Now, we are ready to validate both our product and the associated medium-capacity production line that we have built up during the year. We look forward to these next steps and the product release during the fall, says AcouSort’s CEO Torsten Freltoft.

In 2020, AcouSort developed a quality management system to become an ISO13485-certified supplier of OEM components to the life science industry. AcouPlasma Optical is the first product being developed within that quality system. The production line for semi-automated production is already in place and AcouSort will release additional commercial material during 2021 highlighting the commercial offering of the AcouPlasma Optical OEM module.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.